With medical know-how persevering with to evolve and provide the newest options and therapy to sufferers, Samsung Electronics Switzerland has been aiding the development by growing its merchandise.
Samsung collaborated with Bottneuro AG, a Swiss MedTech startup devoted to enhancing the prognosis and therapy of Alzheimer’s illness and to convey an progressive and enhanced diagnostic and therapy resolution to sufferers. Bottneuro AG has chosen Samsung Galaxy Tab S8+ 5G Enterprise Version {hardware} to retailer and report remedy knowledge within the Bottneuro Answer.
Highly effective Remedy By Revolutionary Applied sciences
Bottneuro AG’s know-how identifies areas of the mind affected by the illness by 3D magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging knowledge. As soon as recognized, these areas may be focused and electronically stimulated with Miamind® neurostimulator know-how. The Galaxy Tab S8+ 5G Enterprise Version simplify dealing with the Bottneuro resolution through a graphical interface.
Sufferers who are suffering from dementia typically expertise decreased cognitive perform within the early phases of the illness, making the necessity for locating a tool that’s simple to function and perceive crucial for Bottneuro AG. With its intuitive interface and value, the Galaxy Tab S8+ 5G Enterprise Version offered the optimum {hardware} for the Bottneuro resolution.
“We have been searching for a easy and dependable resolution for our software. We discovered it with the Galaxy Tab S8+ 5G Enterprise Version and Samsung is giving us nice help within the growth,” stated Julius Klaas, CTO of Bottneuro AG.
Seamless Options in a Single Galaxy Pill
The Galaxy Tab S8+ 5G Enterprise Version provides a plethora of options and capabilities. It comes with a high-resolution Tremendous AMOLED show offering sensible readability for each sufferers and healthcare suppliers and provides dependable long-lasting battery life.
The Miamind® neurostimulator can also be instantly powered by the Galaxy Tab S8+ 5G Enterprise Version, and as soon as therapy is full, the Galaxy Tab S8+ robotically transmits diagnostic and therapy data contained inside the Bottneuro resolution to Bottneuro AG through 5G knowledge connectivity, permitting sufferers to remain within the consolation of their house. Moreover, the Galaxy Tab S8+ 5G Enterprise Version may be individually configured by Samsung Knox, holding delicate knowledge and medical data non-public and guarded.
Partnerships for the Future
Groundbreaking improvements equivalent to these wouldn’t be doable with out partnerships, and Samsung is proud to have been supporting and dealing with Bottneuro AG since its founding in 2021.
“We’re happy to supply Bottneuro AG a dependable, secure and easy resolution with Samsung Knox and to help their novel remedy strategy,” added Daniele Casella, Head of MX B2B Cellular at Samsung Switzerland.
The effectiveness of Bottneuro AG’s new therapeutic therapy might be examined in a number of scientific research this yr. Whereas the therapy isn’t commercially out there but, Bottneuro AG and Samsung stay optimistic about progress that may be made to deal with Alzheimer’s illness.
For extra data on Bottneuro AG and Samsung’s partnership, go to Samsung Newsroom Switzerland, www.bottneuro.com or www.miamind.com.